{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T08:05:34Z","timestamp":1773734734370,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.tips.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T22:30:27Z","timestamp":1443738627000},"page":"628-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Biologic Approaches to Treat Substance-Use Disorders"],"prefix":"10.1016","volume":"36","author":[{"given":"Phil","family":"Skolnick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2015.07.002_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.07.002_bib0205","series-title":"Neurobiology of Mental Illness","first-page":"235","article-title":"Pharmacotherapy of substance use disorders","author":"Acri","year":"2013"},{"key":"10.1016\/j.tips.2015.07.002_bib0210","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.tips.2015.07.002_bib0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0091-3057(78)90295-2","article-title":"Effects of passive immunization against morphine on heroin self-administration","volume":"9","author":"Killian","year":"1978","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2015.07.002_bib0220","doi-asserted-by":"crossref","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2015.07.002_bib0225","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2015.07.002_bib0230","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen. Psychiatry"},{"key":"10.1016\/j.tips.2015.07.002_bib0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/187152711799219352","article-title":"Immunotherapy for drug abuse","volume":"10","author":"Shen","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.tips.2015.07.002_bib0240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1755-5949.2011.00288.x","article-title":"Reanalysis of methamphetamine dependence treatment trial","volume":"18","author":"Winchell","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.tips.2015.07.002_bib0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/erv.13.13","article-title":"Therapeutic vaccines against tobacco addiction","volume":"12","author":"Fahim","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.tips.2015.07.002_bib0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.tips.2015.07.002_bib0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2015.07.002_bib0260","doi-asserted-by":"crossref","first-page":"e76557","DOI":"10.1371\/journal.pone.0076557","article-title":"Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice","volume":"8","author":"Pryde","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2015.07.002_bib0265","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.tips.2015.07.002_bib0270","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tips.2015.07.002_bib0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.intimp.2013.03.021","article-title":"Enhancing immunogenicity of a 3\u2019aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates","volume":"16","author":"McCluskie","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2015.07.002_bib0280","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2013.114","article-title":"Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter","volume":"38","author":"Maoz","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2015.07.002_bib0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/erv.13.1","article-title":"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse","volume":"12","author":"Brimijoin","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.tips.2015.07.002_bib0290","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4161\/19420862.2014.976431","article-title":"First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.tips.2015.07.002_bib0295","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.2174\/1381612811319310004","article-title":"Optimizing the yield of recombinant pharmaceutical proteins in plants","volume":"19","author":"Twyman","year":"2013","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.tips.2015.07.002_bib0300","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1074\/jbc.C300470200","article-title":"Engineered human IgG antibodies with longer serum half-lives in primates","volume":"279","author":"Hinton","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2015.07.002_bib0305","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2015.07.002_bib0310","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2174\/187152711799219398","article-title":"Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users","volume":"10","author":"Brimijoin","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.tips.2015.07.002_bib0315","doi-asserted-by":"crossref","first-page":"16656","DOI":"10.1073\/pnas.0507332102","article-title":"Computational redesign of human butyrylcholinesterase for anticocaine medication","volume":"102","author":"Pan","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2015.07.002_bib0320","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/mol.108.049486","article-title":"Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity","volume":"75","author":"Gao","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2015.07.002_bib0325","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/sj.npp.1301666","article-title":"A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats","volume":"33","author":"Brimijoin","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2015.07.002_bib0330","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4155\/fmc.11.171","article-title":"Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?","volume":"4","author":"Zheng","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.tips.2015.07.002_bib0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1369-1600.2011.00424.x","article-title":"Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys","volume":"18","author":"Schindler","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.tips.2015.07.002_bib0340","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/10550887.2014.969603","article-title":"A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects","volume":"33","author":"Nasser","year":"2014","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.tips.2015.07.002_bib0345","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.450","article-title":"Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects","volume":"55","author":"Cohen-Barak","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2015.07.002_bib0350","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/JCP.0000000000000347","article-title":"Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase (Albu-BChE) and intravenously administered cocaine in recreational cocaine users","volume":"35","author":"Loupe","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tips.2015.07.002_bib0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cbi.2008.04.024","article-title":"An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties","volume":"175","author":"Gao","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tips.2015.07.002_bib0360","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","article-title":"Modafinil for the treatment of methamphetamine dependence","volume":"120","author":"Anderson","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.tips.2015.07.002_bib0365","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2015.01.036","article-title":"Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial","volume":"150","author":"Anderson","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.tips.2015.07.002_bib0370","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jamapsychiatry.2013.872","article-title":"A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence","volume":"70","author":"Somoza","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tips.2015.07.002_bib0375","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2015.07.002_bib0380","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/npp.2014.3","article-title":"Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity","volume":"39","author":"Zlebnik","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2015.07.002_bib0385","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ni.2321","article-title":"Immune to addiction: the ethical dimensions of vaccines against substance abuse","volume":"13","author":"Young","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2015.07.002_bib0390","series-title":"Beautiful Boy: A Father's Journal Through His Son's Addiction","author":"Sheff","year":"2008"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614715001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614715001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T15:19:27Z","timestamp":1653232767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614715001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0165614715001418"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2015.07.002","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Approaches to Treat Substance-Use Disorders","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}